Sexual enhancement supplement recalled over three undeclared drugs

lomitapideflibanserin increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

• Flibanserin was developed by Boehringer Ingelheim, later licensed to Sprout Pharmaceuticals.
• It is considered a "female Viagra," though its mechanism differs from male erectile drugs.
• The medication is part of the growing field of female sexual dysfunction treatment.
• Most clinical trials showed a modest increase in satisfying sexual events.
• Flibanserin should be taken consistently for best results.
• It is not recommended for women who are pregnant or breastfeeding.
• Common adverse reactions include dry mouth and insomnia.
• The drug was approved after extensive clinical trials involving thousands of women.
• Long-term safety data is still being collected.

Reduce lomitapide dose if coadministered with weak CYP3A4 inhibitors (see Dosage Modifications in drug monograph). flibanserin increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. lomustinelomustine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Medical uses

isradipineisradipine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. isradipine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. istradefyllineistradefylline will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Istradefylline 40 mg/day increased peak levels and AUC of CYP3A4 substrates in clinical trials. This effect was not observed with istradefylline 20 mg/day.

Postmarketing Reports

Consider dose reduction of sensitive CYP3A4 substrates. istradefylline will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. lansoprazolelansoprazole will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. lansoprazole will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. larotrectiniblarotrectinib will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. lomustine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

losartanlosartan will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. losartan will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. lovastatinlovastatin will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Other uses for this medicine

glyburideglyburide will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. glyburide will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. hydralazinehydralazine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. hydralazine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. ifosfamideifosfamide will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Common Adverse Effects

ifosfamide will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. irbesartanirbesartan will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. irbesartan will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. isoniazidisoniazid will increase the level or effect of flibanserin by affecting hepatic enzyme CYP2C19 metabolism. isoniazid will increase the level or effect of flibanserin by affecting hepatic enzyme CYP2C19 metabolism. lovastatin will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Information & Authors

larotrectinib will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Either increases effects of the other by sedation. Dosage adjustment may be necessary if lemborexant is coadministered with other CNS depressants because of potentially additive effects. lenvatiniblenvatinib will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. lenvatinib will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. lumacaftor/ivacaftorlumacaftor/ivacaftor will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

• Flibanserin's mechanism involves increasing dopamine and norepinephrine and decreasing serotonin levels.
• It does not address libido caused by relationship issues or physical health problems.
• Flibanserin was once controversial due to debates over its effectiveness.
• It is not suitable for women taking certain antidepressants due to drug interactions.
• The medication has warnings for severe hypotension and syncope.
• Patients are advised to avoid alcohol consumption completely while on the drug.
• Flibanserin's approval was considered a breakthrough for female sexual health.
• Insurance coverage for flibanserin varies and can be limited.
• The drug's marketing emphasizes the importance of patient counseling.

lumacaftor/ivacaftor will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. lurasidonelurasidone will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

INDICATION AND IMPORTANT SAFETY INFORMATION INCLUDING BOXED WARNING

fluvoxaminefluvoxamine will increase the level or effect of flibanserin by affecting hepatic enzyme CYP2C19 metabolism. May increase risk of hypotension, syncope, and CNS depression fosphenytoinfosphenytoin will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. fosphenytoin will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. gabapentin enacarbilgabapentin enacarbil and flibanserin both increase sedation. gabapentin enacarbil and flibanserin both increase sedation.

Before taking flibanserin,

gemfibrozilgemfibrozil will increase the level or effect of flibanserin by affecting hepatic enzyme CYP2C19 metabolism. gemfibrozil will increase the level or effect of flibanserin by affecting hepatic enzyme CYP2C19 metabolism. ginkgo bilobaginkgo biloba will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. ginkgo biloba will increase the level or super p force pill effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. flibanserin will increase the level or effect of glecaprevir/pibrentasvir by P-glycoprotein (MDR1) efflux transporter. Increased flibanserin adverse effects may occur if coadministered with multiple weak CYP3A4 inhibitors.flibanserin, lurasidone.

WHY is this medicine prescribed?

fentanyl transmucosalfentanyl transmucosal and flibanserin both increase sedation. fentanyl transmucosal and flibanserin both increase sedation. fexinidazolefexinidazole will increase the level or effect of flibanserin by affecting hepatic enzyme CYP2C19 metabolism. fexinidazole will increase the level or effect of flibanserin by affecting hepatic enzyme CYP2C19 metabolism. fluconazolefluconazole will increase the level or effect of flibanserin by affecting hepatic enzyme CYP2C19 metabolism.

What should I know about Addyi before using it?

fluconazole will increase the level or effect of flibanserin by affecting hepatic enzyme CYP2C19 metabolism. fluoxetinefluoxetine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. fluoxetine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. fluvastatinfluvastatin will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. fluvastatin will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. lurasidone will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. mavorixaforflibanserin will increase the level or effect of mavorixafor by P-glycoprotein (MDR1) efflux transporter.

Peds Dosing .

ergotamine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. ethinylestradiolethinylestradiol will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. ethinylestradiol will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. etoposideetoposide will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. etoposide will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Approval Year

etravirineetravirine will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. etravirine will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. fedratinibfedratinib will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Adjust dose of drugs that are CYP3A4 substrates as necessary.fedratinib will increase the level or effect of flibanserin by affecting hepatic enzyme CYP2C19 metabolism. Adjust dose of drugs that are CYP2C19 substrates as necessary. Monitor mavorixafor if coadministered with P-gp inhibitors and reduce mavorixafor dose if needed.

flibanserin will increase the level or effect of mavorixafor by P-glycoprotein (MDR1) efflux transporter. mefloquinemefloquine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. mefloquine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. mestranolmestranol will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

mestranol will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Risk for sedation increased if flibanserin is coadministration with other CNS depressants.methadone will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Problems and controversies

fedratinib will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Adjust dose of drugs that are CYP3A4 substrates as necessary. felodipinefelodipine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. felodipine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Coadministration with drugs that increase serotoninergic effects may increase the risk of serotonin syndrome.

Missed Dose

Risk for sedation increased if flibanserin is coadministration with other CNS depressants.fentanyl will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. fentanyl intranasalfentanyl intranasal and flibanserin both increase sedation. fentanyl intranasal and flibanserin both increase sedation. fentanyl transdermalfentanyl transdermal and flibanserin both increase sedation. fentanyl transdermal and flibanserin both increase sedation.